No Data
Galmed Pharmaceuticals' Aramchol Study: Key Updates and Market Implications
Express News | Galmed Pharmaceuticals Presents Late-Breaking Abstract At HEP-DART 2025 Meeting
Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
Galmed Pharmaceuticals Expands Aramchol's Clinical Applications and Strengthens Financial Position
Galmed Issues CEO Letter to Shareholders
Galmed Pharmaceuticals: Q3 Earnings Snapshot